Wise tumbles as US regulator rejects banking licence application
Wise Group PLC (LSE:WISE, NASDAQ:WSE) shares fell 9% to 824p after US regulators rejected its application for a national trust bank charter. The US Office...
Wise Group PLC (LSE:WISE, NASDAQ:WSE) shares fell 9% to 824p after US regulators rejected its application for a national trust bank charter. The US Office...
Freeport-McMoRan Inc (NYSE:FCX, XETRA:FPMB) reported stronger-than-expected second quarter 2026 results on Thursday, with earnings and revenue topping Wall...
Custom Health Holdings Inc (TSX:CHLT) just landed Buy-rated coverage from Stifel, with analysts setting a C$12 price target and pointing to upside as high...
PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating Humana Inc. (NYSE: HUM) (“Humana”) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/case/humana/ Recently a federal securities fraud complaint was filed against Humana on behalf of certain investors who purchased shares of the company's stock between July 27, 2022 and October 1, 2024 (the “Wrongdoing Period”). According to the compla.
Seagate Technology shares continued to advance as demand for high-capacity storage tied to AI data-center buildouts supported further positive earnings revisions. On balance, the Fund's artificial intelligence positioning was a net positive contributor to relative performance during the quarter. We added the Humana position on the view that earnings are at a cyclical trough, with MA margins currently depressed, in some cases negative, as elevated medical cost trends have outpaced premium growth across the industry.
Humana (HUM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
California Public Employees Retirement System reduced its holdings in shares of Humana Inc. (NYSE: HUM) by 24.4% during the undefined quarter, according to its most recent 13F filing with the SEC. The fund owned 171,183 shares of the insurance provider's stock after selling 55,174 shares during the period. California Public Employees Retirement System
Does Humana (HUM) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here is how Humana (HUM) and Envoy Medical, Inc. (COCH) have performed compared to their sector so far this year.
Humana (HUM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
A weight-loss prescription that runs $149 to $449 a month at the pharmacy counter now costs some Medicare enrollees $50. Across a year, that is the difference between roughly $600 and more than $4,000, and whether you capture the savings depends on a coverage question most people do not realize they are answering.
Humana targets a 3% Medicare Advantage margin by 2028 while pursuing 25% 2026 membership growth and rebuilding profitability despite industry headwinds.
Did Humana Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, July 3, 2026
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
LOUISVILLE, Ky.--(BUSINESS WIRE)--The Humana Foundation, the philanthropic arm of Humana Inc. (NYSE: HUM) for the past 45 years, today announced its first slate of 2026 grants, dedicating over $12.2 million to programs and research focused on emotional well-being. The funding will support 13 nonprofit organizations and five university research teams focused on combating loneliness, depression and social isolation among seniors and veterans nationwide. The 2026 national grants scale the Foundati.
O'Reilly's extensive experience across healthcare compliance, risk management, regulatory oversight and payer operations expected to support Dario's continued expansion with health plans, employers and providers as Dario moves closer to care O'Reilly's track record of leveraging advanced data analytics and AI in supporting value-based care strongly aligned with Dario's AI transition NEW YORK, June 30, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in AI-enabled digital health solutions, today announced the appointment of Sean O'Reilly to its Advisory Board. The appointment reflects Dario's continued focus on strengthening its strategic guidance as the Company advances its channel partner-led growth strategy and moves closer to care across the payer, provider and employer markets.
CenterWell's rapid growth is helping HUM expand beyond insurance with integrated care, acquisitions, AI and a 2026 revenue target of at least $25B.
Swedish care provider Ambea said on Monday it had made a recommended public offer for peer Humana , valuing the company at about 2.96 billion Swedish crowns ($304.13 million).
HUM is shifting from membership growth to profitability, with lower medical costs, rising CenterWell revenues, and a margin recovery plan through 2028.
Humana Inc. (NYSE: HUM) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Regarding Healthcare Utilization Costs, Over